Ayvakit

Active Ingredient(s): Avapritinib
FDA Approved: * January 9, 2020
Pharm Company: * BLUEPRINT MEDICINES
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ayvakit Overview

Avapritinib, sold under the brand name Ayvakit, is a medication used for the treatment of tumors due to one specific rare mutation: It is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.[1] Common side effects are edema (swelling), nausea, fatigue/asthenia (abnormal physical weakness or lack of energy), cognitive impairment, vomiting, dec...

Read more Ayvakit Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Avapritinib

Recent Ayvakit Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Avapritinib
  • Tablet: 100mg, 200mg, 300mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ayvakit: (3 results)

Sorted by National Drug Code
  • 72064-110 Ayvakit 100 mg Oral Tablet, Film Coated by Blueprint Medicines Corporation
  • 72064-120 Ayvakit 200 mg Oral Tablet, Film Coated by Blueprint Medicines Corporation
  • 72064-130 Ayvakit 300 mg Oral Tablet, Film Coated by Blueprint Medicines Corporation

Other drugs which contain Avapritinib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 30 March 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA